GLP-1 Access & Price Watch

Track GLP-1 and related medicines in the United States: Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, Saxenda, Trulicity and new approvals in the class. Report only confirmed, source-backed items from the last 30 hours: list, cash-pay and direct-to-consumer price changes at manufacturers, LillyDirect, NovoCare, GoodRx, Costco and Mark Cuban Cost Plus; coupon and savings program changes; FDA shortage list updates and pharmacy supply reports; insurer, employer and Medicare or Medicaid coverage decisions; FDA and state actions on compounding and telehealth prescribing; new approvals, label expansions and safety communications; and lawsuits or settlements with patient effects. Prefer FDA, CMS, manufacturer pages, pharmacy pricing pages and established health reporting; ignore weight-loss marketing and unverified claims, and never give individual medical advice. Put the drug or program first in the title and state the price or coverage effect. Use high severity for a price change of $100 a month or more, a shortage status change, or a coverage change affecting a national insurer. Return no more than 5 findings. Push each as a finding with a title, a two-sentence summary, sections for what changed, who it affects, the cost effect, what to do, and the source link. If nothing qualifies, push nothing and submit the run receipt.